(-0.02%) 5 468.04 points
(-0.35%) 38 975 points
(0.34%) 17 779 points
(0.37%) $81.13
(-3.23%) $2.67
(-0.88%) $2 310.20
(-0.27%) $28.79
(1.61%) $1 002.30
(0.28%) $0.936
(0.72%) $10.68
(0.38%) $0.791
(-0.08%) $87.42
Live Chart Being Loaded With Signals
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms...
Stats | |
---|---|
本日の出来高 | 62 326 |
平均出来高 | 669 787 |
時価総額 | 141.81M |
EPS | $-2.43 ( Q1 | 2024-03-31 ) |
次の収益日 | ( $-0.0600 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.19 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0110 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-11-16 | Kay Mark A | Sell | 12 500 | Stock Option (right to buy) |
2022-11-16 | Enyedy Mark J | Sell | 12 500 | Stock Option (right to buy) |
2022-11-16 | Nacht Mariana | Sell | 100 000 | Stock Option (right to buy) |
2022-11-16 | Wyzga Michael S | Sell | 12 500 | Stock Option (right to buy) |
2022-11-16 | Chereau Frederic | Sell | 328 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
-97.72 |
Last 94 transactions |
Buy: 5 628 346 | Sell: 1 216 285 |
ボリューム 相関
LogicBio Therapeutics, 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
LogicBio Therapeutics, 相関 - 通貨/商品
LogicBio Therapeutics, 財務諸表
Annual | 2023 |
収益: | $287.00M |
総利益: | $59.00M (20.56 %) |
EPS: | $-13.36 |
FY | 2023 |
収益: | $287.00M |
総利益: | $59.00M (20.56 %) |
EPS: | $-13.36 |
FY | 2021 |
収益: | $5.41M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.240 |
FY | 2020 |
収益: | $3.45M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.290 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
LogicBio Therapeutics,
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company\'s GeneRide technology is a new approach to precise gene insertion harnessing a cell\'s natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children\'s Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。